About this opportunity:
At Freenome, we are seeking a Senior Research Associate to help grow our Genomics Assay Development team. At Freenome, you will help develop the assay technologies used to analyze patient samples and contribute to our mission of early cancer detection. The ideal candidate will work to develop assay technologies for our multiomic platform manually and on robotic platforms. You will develop, characterize, verify, and validate clinical-grade assays to measure complex, blood-based analytes (e.g., whole-genome sequencing of cfDNA). You will work cross-functionally with Research & Development teams, automation and process engineering, computational science, and clinical operations to develop and transfer NGS-based assays in a regulated, high-throughput environment. You are passionate about developing life saving diagnostics using NGS technologies, and you will have a significant impact on the continued growth of an organization dedicated to changing the entire landscape of cancer.
The role reports to the Manager of Genomics Late Stage Development. This role will be an onsite role based in our Brisbane, California headquarters.
What you’ll do:
Must haves:
Nice to haves:
Additional information:
Contractors may be hired through a third-party provider and will be considered contingent workers. We invite you to check out our career page @ freenome.com/job-openings/ for additional company information.
Freenome is proud to be an equal opportunity employer and we value diversity. Freenome does not discriminate on the basis of race, color, religion, marital status, age, national origin, ancestry, physical or mental disability, medical condition, pregnancy, genetic information, gender, sexual orientation, gender identity or expression, veteran status, or any other status protected under federal, state, or local law.
Applicants have rights under Federal Employment Laws.
#LI-ONSITE

Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease.
To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas.
We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures.
A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.